ARTICLE | Company News
Management tracks
July 25, 2015 1:12 AM UTC
Gene therapy play Avalanche Biotechnologies Inc. (NASDAQ:AAVL) said Thomas Chalberg resigned as president, CEO and a director. EVP of Business Operations Hans Hull will be interim CEO.
Oncology play Mologen AG (Xetra:MGN) named Mariola Soehngen CEO, effective Nov. 1. Soehngen will remain CMO at Paion AG (Xetra:PA8) through Oct. 31. ...